BioNexus Gene Lab Corp. (BGLC) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $20.17M; Additional Paid in CapitalUSD $-5.01M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-127.21K; Retained Earnings (Accumulated Deficit)USD $-7.26M.
- 2026-03-31: Common Stock, Value, IssuedUSD $20.17M; Additional Paid in CapitalUSD $-5.01M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-98.85K; Retained Earnings (Accumulated Deficit)USD $-6.97M.
- 2025-12-31: Common Stock, Value, IssuedUSD $20.17M; Additional Paid in CapitalUSD $-5.01M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-120.75K; Retained Earnings (Accumulated Deficit)USD $-6.43M.
- 2025-09-30: Common Stock, Value, IssuedUSD $17.33M; Additional Paid in CapitalUSD $-5.01M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-112.55K; Retained Earnings (Accumulated Deficit)USD $-5.39M.
BioNexus Gene Lab Corp. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | AOCI Including Portion Attributable to Noncontrolling Interest, before Tax USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.17M | $-5.01M | $-127.21K | $-7.26M | $7.78M | (m) | (m) | (m) |
| 2026-03-31 | $20.17M | $-5.01M | $-98.85K | $-6.97M | $8.09M | (m) | (m) | (m) |
| 2025-12-31 | $20.17M | $-5.01M | $-120.75K | $-6.43M | $8.61M | (m) | (m) | (m) |
| 2025-09-30 | $17.33M | $-5.01M | $-112.55K | $-5.39M | $6.82M | (m) | (m) | (m) |
| 2025-06-30 | $17.33M | $-5.01M | $-115.76K | $-4.68M | $7.52M | (m) | (m) | (m) |
| 2025-03-31 | $17.33M | $-5.01M | $-482.84K | $-4.07M | $7.77M | (m) | (m) | (m) |
| 2024-12-31 | $17.33M | $-5.01M | $-555.00K | $-3.44M | $8.32M | (m) | (m) | (m) |
| 2024-09-30 | $17.33M | $-5.01M | $-162.05K | $-3.09M | $9.39M | (m) | (m) | (m) |
| 2024-06-30 | $17.19M | $-5.01M | $-884.74K | $-1.75M | $9.55M | (m) | (m) | (m) |
| 2024-03-31 | $17.19M | $-5.01M | $-887.20K | $-1.95M | $9.34M | (m) | (m) | (m) |
| 2023-12-31 | $17.19M | $-5.01M | $-677.29K | $-1.84M | $9.66M | (m) | 12 month · $511.74K | (m) |
| 2023-09-30 | $17.28M | $-5.01M | $-800.60K | $-1.78M | $9.32M | (m) | (m) | (m) |
| 2023-06-30 | $10.93M | $-5.01M | $-781.99K | $828.08K | $5.59M | (m) | (m) | (m) |
| 2023-03-31 | $10.93M | $-5.01M | $-448.10K | $1.09M | $6.19M | (m) | (m) | (m) |
| 2022-12-31 | $10.93M | $-5.01M | $-409.06K | $1.16M | $6.67M | (m) | 12 month · $0.00 | (m) |
| 2022-09-30 | $10.93M | $-5.01M | $-807.39K | $1.31M | $6.42M | (m) | (m) | (m) |
| 2022-06-30 | $10.93M | $-5.01M | $-486.80K | $1.39M | $6.82M | (m) | (m) | (m) |
| 2022-03-31 | $10.78M | $-5.01M | $-169.04K | $1.53M | $7.13M | (m) | (m) | (m) |
| 2021-12-31 | $10.78M | $-5.01M | $-100.26K | $1.51M | $7.18M | (m) | (m) | (m) |
| 2021-09-30 | $10.78M | $-5.01M | $-139.19K | $1.42M | $7.05M | (m) | (m) | (m) |
| 2021-06-30 | $10.78M | $-5.01M | $-82.25K | $1.13M | $6.81M | (m) | (m) | (m) |
| 2021-03-31 | $10.78M | $-5.01M | $-74.78K | $1.10M | $6.79M | (m) | (m) | (m) |
| 2020-12-31 | $10.78M | $-5.01M | $133.68K | $760.79K | $6.66M | (m) | (m) | (m) |
| 2020-09-30 | $6.48M | $-5.01M | $-33.35K | $-507.84K | $6.68M | $661.00 | (m) | (m) |
| 2020-06-30 | $6.48M | $-5.01M | $-55.29K | $-447.80K | $6.20M | $-7.95K | (m) | (m) |
| 2020-03-31 | $6.48M | $-5.01M | $-58.78K | $-381.26K | $6.19M | $-8.87K | (m) | (m) |
| 2020-01-01 | (m) | (m) | (m) | (m) | $1.12M | (m) | (m) | (m) |
| 2019-12-31 | $6.48M | $-5.01M | $-17.10K | $-333.31K | $1.12M | $6.14K | (m) | (m) |
| 2019-09-30 | $6.55M | $-5.01M | $-38.23K | $-240.73K | $1.26M | $-1.01K | (m) | (m) |
| 2019-06-30 | $6.65M | $-5.01M | $-27.43K | $-218.71K | $1.39M | (m) | (m) | (m) |
| 2019-03-31 | $6.65M | $-5.01M | $-9.83K | (m) | $1.48M | (m) | (m) | $-148.31K |
| 2018-12-31 | $6.65M | $-5.01M | $-26.98K | $-86.84K | $1.52M | $2.77K | (m) | $-86.84K |
| 2018-01-01 | (m) | (m) | (m) | (m) | $94.63K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |